The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
At the same time, emerging results from lower-risk MDS studies raise the possibility that earlier intervention could alter the natural history of the disease. In the COMMANDS trial, luspatercept produced higher and more durable rates of transfusion independence than epoetin alfa.
At 8 am on Wednesday, September 9 during the SOHO 2026 Annual Meeting, Nirav Shah, MD, will lead a Meet-the-Professor session on pharma trials in lymphoma. Watch Loretta Nastoupil, MD, discuss the topic and point of care, CAR-T manufacturing with Dr. Shah.
The conversation covers how funding organizations support the international MDS research community by deploying flexible financial resources, offering faculty transition awards to build the scientific pipeline, and providing Discovery Research Grants to advance individual projects.
Each year, SOHO awards travel scholarships to budding early-career physicians and researchers to attend the SOHO Annual Meeting in Houston, Texas, to present their research.
Rami Komrokji, MD, of the Moffitt Cancer Center in Tampa, Florida, and colleagues will present the findings at the 2026 SOHO Annual Meeting.
The study, led by Raúl Azibeiro Melchor, of Hospital Universitario de Salamanca in Spain, will be presented at the Fourteenth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
